Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: Relationships to insulin resistance and endothelial dysfunction

European Journal of Endocrinology

Volumn 164, Issue 1, 2011, Pages 61-68

  Pepene, Carmen Emanuela ^a   Ilie, Ioana Rada ^a   Marian, Ioan ^a   Duncea, Ileana ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; INSULIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; ANDROGEN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY COMPOSITION; BRACHIAL ARTERY; CAROTID ARTERY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VASODILATATION; ANDROGEN BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTERY INTIMA PROLIFERATION; DISEASE ASSOCIATION; ENDOTHELIUM INJURY; ESTRADIOL BLOOD LEVEL; FAT MASS; GLYCEMIC CONTROL; HYPERANDROGENISM; MOLECULAR PATHOLOGY; OBESITY; PROGNOSIS; TESTOSTERONE BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; BODY COMPOSITION; BRACHIAL ARTERY; CAROTID ARTERIES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; OSTEOPROTEGERIN; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REGRESSION ANALYSIS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TUNICA INTIMA; TUNICA MEDIA; VASODILATION;

EID: 78751558479     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0720     Document Type: Article

References (42)

1. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W & Osdoby P. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. Journal of Biological Chemistry 2001 276 20659-20672. (doi:10.1074/jbc.M010153200)
2. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T & Khosla S. Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochemical and Biophysical Research Communications 2001 280 334-339. (doi:10.1006/bbrc.2000.4130) (Pubitemid 32917516)
3. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C & Daemen MJ. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 1998-2003. (doi:10.1161/hq1201.100229)
4. 3-induced NF-κB-dependent survival factor for endothelial cells. Journal of Biological Chemistry 2000 275 20959-20962. (doi:10.1074/jbc.C000290200)
5. Zauli G, Corallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, Tedesco F & Secchiero P. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007 110 536-543. (doi:10.1182/blood-2007-01-068395)
6. Mangan SH, Van Campenhout A, Rush C & Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-α associated with induction of angiopoietin-2. Cardiovascular Research 2007 76 494-505. (doi:10.1016/j.cardiores.2007.07.017)
7. Candido R, Toffoli B, Corallini F, Bernardi S, Zella D, Voltan R, Grill V, Celeghini C & Fabris B. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. Journal of Vascular Research 2010 47 252-261. (doi:10.1159/000257339)
8. Xiang GD, Xu L, Zhao LS, Yue L & Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 2006 55 2126-2131. (doi:10.2337/db06-0231) (Pubitemid 44509988)
9. Shin JY, Shin YG & Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006 29 1664-1666. (doi:10.2337/dc06-0631)
10. Ali Z, Ellington AA, Mosley TH Jr & Kullo IJ. Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. Atherosclerosis 2009 206 575-580. (doi:10.1016/j.atherosclerosis.2009.03.032)
11. Shargorodsky M, Boaz M, Luckish A, Matas Z, Gavish D & Mashavi M. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis 2009 204 608-611. (doi:10.1016/j.atherosclerosis.2008.10.024)
12. Browner WS, Lui LY & Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. Journal of Clinical Endocrinology and Metabolism 2001 86 631-637. (doi:10.1210/jc.86.2.631)
13. Nybo M & Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. European Journal of Endocrinology 2008 159 603-608. (doi:10.1530/EJE-08-0554)
14. Rasmussen LM, Tarnow L, Hansen TK, Parving HH & Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. European Journal of Endocrinology 2006 154 75-81. (doi:10.1530/eje.1. 02049)
15. Yaturu S, Rains J & Jain SK. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-α levels in men with type 2 diabetes. Cytokine 2008 44 168-171. (doi:10.1016/j.cyto.2008.07.471)
16. Nabipour I, Kalantarhormozi M, Larijani B, Assadi M & Sanjdideh Z. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism 2010 59 742-747. (doi:10.1016/j.metabol.2009.09.019)
17. Gannagé-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M & Trak-Smayra V. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. European Journal of Endocrinology 2008 158 353-359. (doi:10.1530/EJE-07-0797)
18. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK & Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001 103 1410-1415. (Pubitemid 32220633)
19. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G & Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 4588-4593. (doi:10.1210/jc.2003-031867)
20. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T & Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. Journal of Clinical Endocrinology and Metabolism 2004 89 5592-5596. (doi:10.1210/jc.2004-0751)
21. Arikan S, Akay H, Bahceci M, Tuzcu A & Gokalp D. The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function. Fertility and Sterility 2009 91 450-455. (doi:10.1016/j.fertnstert.2007.11.057)
22. Diamanti-Kandarakis E, Paterakis T & Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Annals of the New York Academy of Sciences 2006 1092 175-186. (doi:10.1196/annals.1365.015) (Pubitemid 47092336)
23. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E & Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010 95 2038-2049. (doi:10.1210/jc.2009-2724)
24. Escobar-Morreale HF, Botella-Carretero JI, Martínez-García MA, Luque-Ramírez M, Alvarez-Blasco F & San Millán JL. Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. European Journal of Endocrinology 2008 159 225-232. (doi:10.1530/EJE-08-0107)
25. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672. (doi:10.1210/jc.84.10.3666)
26. Rosei EA. Assessment of preclinical target organ damage in hypertension: carotid intima-media thickness and plaque. Blood Pressure 2003 12 185-186.
27. Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E & Tugrul A. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thrombosis Research 2007 120 511-516. (doi:10.1016/j.thromres.2006.12.004)
28. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K & Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002 106 1192-1194. (doi:10.1161/01.CIR. 0000031524.49139.29) (Pubitemid 34988634)
29. Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonné JF, Cristol JP & Dupuy AM. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007 30 2934-2939. (doi:10.2337/dc07-0992)
30. Guang-da X, Hui-ling S & Jie H. Changes in endothelial function and its association with plasma osteoprotegerin in hypothyroidism with exercise-induced silent myocardial ischaemia. Clinical Endocrinology 2008 69 799-803. (doi:10.1111/j.1365-2265.2008.03263.x)
31. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM & Haynes DR. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. Journal of Cellular Physiology 2005 204 714-723. (doi:10.1002/jcp.20354)
32. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, Lekakis J & Panidis D. Inflammatory and endothelial markers in women with polycystic ovary syndrome. European Journal of Clinical Investigation 2006 36 691-697. (doi:10.1111/j.1365-2362.2006.01712.x) (Pubitemid 44393927)
33. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G & Panidis D. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Human Reproduction 2006 21 1426-1431. (doi:10.1093/humrep/del003)
34. Banaszewska B, Pawelczyk L, Spaczynski RZ & Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. Journal of Clinical Endocrinology and Metabolism 2009 94 4938-4945. (doi:10.1210/jc.2009-1674)
35. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P & Rasmussen LM. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008 51 2100-2107. (doi:10.1007/s00125-008-1123-8)
36. Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS & Choi KM. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clinical Endocrinology 2005 63 594-598. (doi:10.1111/j.1365-2265.2005.02390.x)
37. Malita FM, Messier V, Lavoie JM, Bastard JP, Rabasa-Lhoret R & Karelis AD. Comparison between several insulin sensitivity indices and metabolic risk factors in overweight and obese postmenopausal women: a MONET study. Nutrition, Metabolism, and Cardiovascular Diseases 2010 20 173-179. (doi:10.1016/j.numecd.2009.03.005)
38. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC & Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999 140 4367-4370. (doi:10.1210/en.140.9.4367)
39. Carmina E, Guastella E, Longo RA, Rini GB & Lobo RA. Correlates of increased lean muscle mass in women with polycystic ovary syndrome. European Journal of Endocrinology 2009 161 583-589. (doi:10.1530/EJE-09-0398)
40. Dagogo-Jack S, Al-Ali N & Qurttom M. Augmentation of bone mineral density in hirsute women. Journal of Clinical Endocrinology and Metabolism 1997 82 2821-2825. (doi:10.1210/jc.82.9.2821)
41. Cucinelli F, Paparella P, Soranna L, Barini A, Cinque B, Mancuso S & Lanzone A. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. European Journal of Endocrinology 1999 140 215-223. (doi:10.1530/eje.0.1400215)
42. Mayer L, Walsh BT, Pierson RN Jr, Heymsfield SB, Gallagher D, Wang J, Parides MK, Leibel RL, Warren MP, Killory E & Glasofer D. Body fat redistribution after weight gain in women with anorexia nervosa. American Journal of Clinical Nutrition 2005 81 1286-1291.